Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biocon, Ltd.
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Biocon Biologics has become the first biosimilar insulins company to partner with the International Diabetes Federation to help increase affordable access to insulin worldwide. The partnership was sealed at the start of centenary celebrations of the discovery of insulin.
Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.
Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.
- Medical Devices
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- Biocon Sdn Bhd.
- Biocon Limited
- Biocon Biologics India Ltd
- Bicara Therapeutics